Analysis of PLAGL1 expression in thyroid carcinomas

VICTORIA PEYRET; DEMIAN SLODKI; CELESTE GEYSELS; MARCELO MONTEROS ALVI; JAVIER JALDÍN-FINCATI; JUAN PABLO NICOLA; MARTA ALICIA TOSCANO

Mar del Plata

Congreso; Reunión Conjunta SAIC. SAI. SAFIS. LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2022

SAIC. SAI. SAFIS

The PLAGL1 gene encodes for a zinc finger transcription factor proposed to act as a tumor suppressor involved in cell cycle arrest and apoptosis. However, PLAGL1 is overexpressed in some neoplasms suggesting an oncogenic function. Our aim was to study PLAGL1 expression in Thyroid Carcinomas (TC) and the association between high PLAGL1 levels and poor prognosis. PLAGL1 expression was evaluated by IHC in human thyroid tissue samples and by RT-PCR and Western blot on a large panel of human thyroid cell lines. For transcriptomic analysis we downloaded datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data from papillary thyroid carcinomas (PTC). DNA methylation analysis and clinical characteristics were obtained from the PTC-TCGA dataset. We detected the expression of the large and short isoforms of PLAGL1 in different TC cell lines. Furthermore, in TC samples, we identified cytoplasmic and nuclear expression of PLAGL1. Transcriptomic analysis indicated a significant (P